Education
About Us
Working with TipRanks
Follow Us
BICO Group AB Class B (CLLKF)
OTHER OTC:CLLKF
RESEARCH TOOLSreports
Earnings Data
Report Date
Aug 19, 2025TBA Not Confirmed
Period Ending
2025 (Q2)Consensus EPS Forecast
-0.07Last Year’s EPS
-0.11Same Quarter Last Year
Based on 0 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Apr 29, 2025
|% Change Since: -6.72%
|Next Earnings Date:Aug 19, 2025
Earnings Call Sentiment|Neutral
The earnings call presents a mixed picture. While there are strategic divestments and specific areas of growth, such as Bioprinting and Life Science Solutions, the company faces significant challenges with negative organic growth, especially in Lab Automation, and broader macroeconomic uncertainties impacting its performance.Company Guidance
During BICO's Q1 2025 earnings call, CEO Maria Forss and CFO Jacob Thordenberg provided detailed guidance on the company's financial performance and strategic initiatives. The quarter's sales amounted to SEK 389 million, reflecting a negative organic growth of 19%, while adjusted EBITDA remained stable at negative SEK 12 million, with a margin of negative 3%. The company reported a cash flow from operating activities of SEK 77 million and a significant reduction in net working capital to 12% of last 12-month sales. BICO also highlighted plans to transition into a net cash position in Q2 2025 following the divestment of MatTek and Visikol, expected to generate $80 million. This strategy aligns with their focus on lab automation and selected workflows, as well as efforts to mitigate macroeconomic uncertainties, including potential tariffs. The company has strategically moved manufacturing out of China and adjusted logistics to enhance cost efficiency. BICO's business areas showed varied performance, with Life Science Solutions and Bioprinting experiencing growth, while Lab Automation faced challenges due to fewer project starts and a strong comparison quarter in 2024.Divestment of MatTek and Visikol
BICO has entered into an agreement to divest MatTek and Visikol to Sartorius for $80 million, which will help move the company into a net cash position during Q2 2025.
Positive Developments in Life Science Solutions and Bioprinting
Despite a decline in overall sales, both Life Science Solutions and Bioprinting showed growth due to operational excellence, with Bioprinting achieving an organic growth of 41%.
Cash Flow from Operating Activities
The cash flow from operating activities was SEK 77 million, which was explained by the cash collection from quarter four sales in 2024.
Improved Gross Margin
Gross margin improved to 54% due to product mix and operational excellence initiatives.
---
CLLKF Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
CLLKF Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Apr 29, 2025 | $3.87 | $3.74 | -3.36% |
| Feb 19, 2025 | $3.50 | $3.98 | +13.71% |
| Nov 26, 2024 | $3.36 | $2.76 | -17.86% |
| Aug 20, 2024 | $4.20 | $4.05 | -3.57% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does BICO Group AB Class B (CLLKF) report earnings?
BICO Group AB Class B (CLLKF) is schdueled to report earning on Aug 19, 2025, TBA Not Confirmed.
What is BICO Group AB Class B (CLLKF) earnings time?
BICO Group AB Class B (CLLKF) earnings time is at Aug 19, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is CLLKF EPS forecast?
CLLKF EPS forecast for the fiscal quarter 2025 (Q2) is -0.07.
---